Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HYPERQTOTAL

Financiado

Cerrado

Diagnosis of Ischemic Heart Disease by means of innovative and highly accurate...

Diagnosis of Ischemic Heart Disease by means of innovative and highly accurate high frequency QRS electrocardiogram analysis Occlusion of the coronary arteries that supply oxygenated blood to the heart muscle is referred to as ischemic heart disease (IHD). IHD is the most common, serious, chronic, life-threatening illness in the developed world. Current... ver más

30/04/2016

BSP - Biological S...

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

BSP BIOLOGICAL SIGNAL PROCESSING LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-04-30

PHC-12-2015-1: Clinical research for the validatio...

I+D

Cerrada hace 9 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

BSP - Biological Signal Proc...

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ECSTATIC Electrostructural Tomography Towards Multiparametric Imagi... 1M€ Cerrado

EVINCI-STUDY Evaluation of Integrated Cardiac Imaging for the Detection a... 3M€ Cerrado

AGLYC The First In Vitro Diagnostic Device for the Early Detection... 3M€ Cerrado

TEC2016-75161-C2-1-R INVESTIGACION TRASLACIONAL Y TRANSFERENCIA DE UN NUEVO SISTE... 206K€ Cerrado

TEC2008-02193 SISTEMA INTEGRAL DE ANALISIS DE LA SEÑAL ELECTRICA CARDIACA... 17K€ Cerrado

TEC2009-13939 DESARROLLO DE TECNICAS AVANZADAS DE ANALISIS Y CARACTERIZACI... 62K€ Cerrado

Duración del proyecto: 4 meses Fecha Inicio: 2015-12-11
Fecha Fin: 2016-04-30

Líder del proyecto

BSP BIOLOGICAL SIGNAL PROCESSING LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Occlusion of the coronary arteries that supply oxygenated blood to the heart muscle is referred to as ischemic heart disease (IHD). IHD is the most common, serious, chronic, life-threatening illness in the developed world. Currently, the most widely used tool for diagnosing IHD is the electrocardiogram (ECG), which records the electrical activity of the cardiac muscle as it generates the stages of the cardiac cycle. Specific changes in the ECG recorded during physical stress protocols are used for the non-invasive detection of IHD. Patients with positive stress test results are usually referred for further investigation. However, the sensitivity of the standard ECG, even during stress tests, is relatively poor, and is generally considered to be between 50% and 70%, and in some studies has been reported to be even lower. That, in other words, means that 30-50% of all IHD patients are not diagnosed correctly by standard stress ECGs. Traditional ECG analysis is performed in the 0.05 – 100Hz frequency range. However, a significant body of evidence accumulated during recent years indicates that higher frequency spectral components of the ECG signal contain valuable information for the detection of IHD. Studies published by Prof. Shimon Abboud, BSP’s chief scientist, and Dr. Amir Beker, BSP’s founder and CEO, have shown that the presence of ischemic pathologies in the heart is highly correlated with specific changes in the high-frequency spectral components of the ECG. BSP has pioneered the clinical implementation of high-frequency ECG and has developed it into a valuable diagnostic application. The company’s proprietary HyperQ™ technology extracts and analyses the high-frequency components of the ECG. BSP has pursued the development of its HyperQ™ technology in two parallel, highly correlated, pathways: (a) acquisition and reliable production of the HyperQ™ signal, and (b) analysis of the HyperQ™ signal for extracting clinical and diagnostic information.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores